AbbVie says Phase 3 AFFIRM trial shows subcutaneous Skyrizi lifts endoscopic remission in Crohn’s disease patients

AbbVie released new Phase 3 AFFIRM results for subcutaneous Skyrizi in moderate-to-severe Crohn’s disease, presented at ACG 2026. Data showed improved intestinal healing outcomes versus placebo, supporting deeper disease control with a self-administered induction regimen. Findings build on previously presented week 12 results that showed Skyrizi beat placebo on clinical remission and endoscopic response. AbbVie is seeking FDA approval for subcutaneous induction dosing in Crohn’s disease, positioning Skyrizi for broader use earlier in treatment. Safety through week 24 aligned with the established profile, with no new safety signals reported. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AbbVie Inc. published the original content used to generate this news brief via (Ref. ID: CG70422) on October 13, 2026, and is solely responsible for the information contained therein. (C)